Navigation Links
WuXi PharmaTech Announces Third Quarter 2008 Results
Date:11/12/2008

Third Quarter Net Revenues Up 98% and Adjusted EBITDA Up 70% Year-Over-Year

SHANGHAI, China, Nov. 12 /Xinhua-PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced its unaudited financial results for the third quarter ended September 30, 2008. During the quarter, WuXi's net revenue increased 98% year-over-year to $67.5 million, and diluted earnings per ADS were $0.10.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

Commenting on the third quarter 2008 results, Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech, said, "WuXi continues to deliver strong revenue and profitability growth, as reflected in 98% year-over-year top-line revenue and 70% adjusted EBITDA growth. As we disclosed in the pre- announcement, the constricted biotech financing environment is impacting the CRO industry. However, we believe the need for outsourced development and manufacturing services will continue to be robust in the longer term. WuXi will continually work with WuXi's customers to bring their programs from bench to the market sooner and less costly.

"We are dedicated to maintaining and expanding WuXi's preferred provider status with our customers. In addition to delivering high-quality, IP- protected services efficiently, we will continue to position WuXi for the future to improve the success of discovery and shorten development time for our customers. This commitment requires us to expand WuXi's capacity and capabilities to meet our customers' expanding needs, from the bench to the market."
Third Quarter 2008 Financial Results (Unaudited, U.S. Dollars in Millions)

GAAP Non-GAAP

The third quarter of The third quarter of

2008 2007 % Growth 2008 2007 % Growth

Net Revenue $67.5 $34.0 98% $67.5 $34.0 98%

Laboratory Services 47.0 26.7 76% 47.0 26.7 76%

Manufacturing Services 20.5 7.3 180% 20.5 7.3 180%

Gross Profit 22.8 16.0 43% 27.4 16.3 68%

Laboratory Services 19.4 12.9 51% 22.8 13.2 73%

Manufacturing Services 3.4 3.1 9% 4.6 3.1 48%

Operating Income 9.0 7.5 20% 16.1 9.0 79%

Net Income 7.3 8.6 (16%) 12.8 10.1 26%

EBITDA 16.8 10.2 64% 19.9 11.7 70%

Numbers presented on a non-GAAP basis exclude share-based compensation expenses, amortization of acquired intangible assets and deferred tax impact on acquired intangible assets. The non-GAAP measures are described below and reconciled to the corresponding GAAP measure in the section below titled "Use of Non-GAAP Financial Measures".

The Company's Laboratory Services include discovery chemistry, service biology, toxicology, pharmaceutical development, analytical services, biopharmaceutical and medical device testing. Net revenues from Laboratory Services increased 76% to $47.0 million in the third quarter 2008 from $26.7 million in the third quarter 2007. Gross profit increased 51% in the third quarter 2008 from $12.9 million in the third quarter 2007. Third quarter 2008 GAAP gross margin was 41%, and non-GAAP gross margin was 49%.

The Manufacturing Services segment focuses on advanced intermediates, active pharmaceutical ingredients (APIs), and biologics-based manufacturing, testing and related services. Net revenues from Manufacturing Services increased 180% to $20.5 million in the third quarter 2008 from $7.3 million in the third quarter 2007. Gross profit increased 9% in the third quarter 2008 from $3.1 million in the third quarter 2007. Third quarter 2008 GAAP gross margin was 16%, and non-GAAP gross margin was 23%.

Revised Full Year 2008 Guidance Confirmed

WuXi confirms its net revenue guidance of $260 to $265 million for the full year 2008, as announced in October 2008. This represents year-over-year revenue growth ranging from 92% to 96%.

WuXi also confirms full-year adjusted EBITDA is expected to be in the range of $70 to $75 million (The forecast excludes any potential future impairment charges and further mark-to-market adjustments on foreign currency forward contracts, if any).

Conference Call

WuXi PharmaTech senior management will host a conference call at 8:00 am (Eastern) / 5:00 am (Pacific) / 9:00 pm (Beijing/Hong Kong) on Thursday, November 13, 2008, to discuss its 2008 third quarter financial results and recent business activities. The conference call may be accessed by calling:

(US) 866-586-2813

(China, Northern Region) 10-800-611-0127

(China, Southern Region) 10-800-361-0079

(HK) 800-965-808

(UK) 0-800-056-9662

(International) +61-2-8524-6650.

Conference ID: 70474888.

A telephone replay will be available two hours after the call's completion until December 14, 2008, at:

(US) 866-214-5335

(HK) 800-901-596

(China) 10-800-140-0386

(UK) 0-800-731-7846

(International) +61-2-8235-5000.

Passcode: 70474888.

A live webcast of the conference call and replay will be available on the investor relations page of WuXi PharmaTech's website at http://www.wuxiapptec.com .

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com .

Use of Non-GAAP Financial Measures

We have provided the third quarter 2007 and 2008 gross profit, operating income, net income on a non-GAAP basis, which excludes share-based compensation expenses, amortization of acquired intangible assets and deferred tax impact on acquired intangible assets. Adjusted EBITDA refers to EBITDA excluding share-based compensation expenses. The Company believes both management and investors benefit from referring to these non-GAAP financial measures (including adjusted EBITDA) in assessing the Company's financial performance and liquidity and when planning and forecasting future periods. These non-GAAP operating measures (including adjusted EBITDA) are useful for understanding and assessing underlying business performance and operating trends. The Company expects to provide gross profit, operating income, net income on a non-GAAP basis using a consistent method on a quarterly basis going forward.

Readers are cautioned not to view non-GAAP results (including adjusted EBITDA) on a stand-alone basis or as a substitute for results under GAAP, or as being comparable to results reported or forecasted by other companies, and should refer to the reconciliation of non-GAAP measures to GAAP measures for the indicated periods attached hereto.

Cautionary Note Regarding Forward-Looking Statements

Statements in this release contain "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the Private Securities Litigation Reform Act of 1995, including, among others, expected net revenue and EBITDA levels for 2008; the global trends in outsourced R&D and manufacturing; and anticipated changes in the pharma business model and the opportunities presented to WuXi as a result of those changes.

These forward-looking statements are not historical facts but instead represent only our belief regarding future events, many of which, by their nature, are inherently uncertain and outside of our control. Our actual results and financial condition and other circumstances may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Among other factors, uncertainty in the global economy may adversely impact our business and the trends for outsourced R&D and manufacturing; Pharma companies may not change their business models as expected or in a manner favorable to us; we may fail to capitalize on the opportunities presented; we may not maintain our preferred provider status with our clients; and may be unable to successfully expand our capabilities to meet client needs. In addition other factors that could cause our actual results to differ from what we currently anticipate include our limited operating history; failure to generate sufficient future cash flows or secure any required future financing on acceptable terms or at all; failure to retain key personnel; effective integration of products and services from AppTec; our reliance on a limited number of customers to continue to account for a high percentage of our revenues; risk of payment failure by any of our large customers, which could significantly harm our cash flows and profitability; dependency upon the continued service of our senior management and key scientific personnel and ability to retain our existing customers or expand our customer base. The financial information contained in this release should be read in conjunction with the consolidated and pro forma financial statements and notes thereto included in our 2007 Annual Report on Form 20-F filed with available on the Securities and Exchange Commission's website at http://www.sec.gov . For additional information on these and other important factors that could adversely affect our business, financial condition, results of operations and prospects, see "Risk Factors" beginning on page 10 of our 2007 Annual Report on Form 20-F. Our results of operations for the third quarter 2008 are not necessarily indicative of our operating results for any future periods. Any projections in this release are based on limited information currently available to us, which is subject to change. Although these projections and the factors influencing them will likely change, we undertake no obligation to update or revise these forward- looking statements, whether as a result of new information, future events or otherwise, after the date of this press release. Such information speaks only as of the date of this release.

WUXI PHARMATECH (CAYMAN) INC.

UNAUDITED CONSOLIDATED BALANCE SHEETS

(in thousands of US Dollars, except ordinary share, ADS and par value data)

September 30, December 31,

2008 2007

Assets:

Current assets:

Cash and cash equivalents 73,274 213,585

Restricted cash 5,070 5,526

Short-term investment 14,666 --

Accounts receivable, net 46,398 18,199

Inventories 12,821 13,352

Prepaid expenses and other current assets 13,229 11,215

Total current assets 165,458 261,877

Non-current assets:

Goodwill 102,255 --

Property, plant and equipment, net 153,681 73,634

Intangible assets, net 37,421 921

Land use rights, net 5,426 5,160

Other non-current assets 1,944 2,183

Total non-current assets 300,727 81,898

Total assets 466,185 343,775

Liabilities and shareholders' equity:

Current liabilities:

Short-term and current portion

of long-term debt 10,180 --

Accounts payable 15,211 7,216

Accrued expenses 12,113 12,279

Deferred revenue 11,452 19,706

Advanced subsidies 1,858 1,077

Other taxes payable 19,455 4,060

Other current liabilities 11,346 1,233

Total current liabilities 81,615 45,571

Non-current liabilities:

Long-term debt, excluding current portion 4,366 4,108

Advanced subsidies 2,144 1,529

Convertible notes 35,864 40,988

Deferred tax liabilities 15,743 181

Other non-current liabilities 3,058 --

Total non-current liabilities 61,175 46,806

Total liabilities 142,790 92,377

Shareholders' equity:

Ordinary shares (Note 1), ($0.02 par

value, 5,002,500,000 authorized

525,020,598 and 492,226,776 issued

and outstanding as of September 30,

2008 and December 31, 2007,

respectively) 10,500 9,845

Additional paid-in capital 320,982 291,020

Accumulated deficit (27,654) (57,302)

Accumulated other comprehensive income 19,567 7,835

Total shareholders' equity 323,395 251,398

Total liabilities and

shareholders' equity 466,185 343,775

Note 1: Eight (8) ordinary shares are equal to one (1) ADS

WUXI PHARMATECH (CAYMAN) INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE THREE MONTHS AND NINE MONTHS ENDED SEPTEMBER 30, 2008 AND 2007

(In thousands of U.S. dollars, except share data and per share data)

Three Months Ended

September 30,

2008 2007 %

Net revenues:

Laboratory services 46,990 26,744 76%

Manufacturing services 20,482 7,305 180%

Total net revenues 67,472 34,049 98%

Cost of revenues:

Laboratory services (27,556) (13,843)

Manufacturing services (17,105) (4,206)

Total cost of revenues (44,661) (18,049)

Gross Profit 22,811 16,000 43%

Operating expenses:

Selling and marketing expenses (2,068) (468) 342%

General and administrative expenses (11,731) (8,032) 46%

Total operating expenses (13,799) (8,500) 62%

Operating income 9,012 7,500 20%

Other income (expenses), net:

Other income (expenses), net (1,067) (9)

Interest income (expenses), net 148 1,334

Total other income (expenses), net (919) 1,325

Income before income taxes 8,093 8,825 (8%)

Income taxes (826) (178)

Net income 7,267 8,647 (16%)

Amount attributed to:

Deemed dividend on issuance and

repurchase of preference shares -- --

Amounts allocated to preference

shares for participating rights to

dividends -- (1,779)

Income attributable to holders of ADS

(Note 2):

Basic 7,267 6,868

Diluted 7,267 6,898

Basic earnings per ADS (Note 2) 0.11 0.15

Diluted earnings per ADS (Note 2) 0.10 0.12

Weighted average ADS outstanding -

basic (Note 2) 64,531,068 44,774,893

Weighted average ADS outstanding -

diluted (Note 2) 72,931,421 55,496,657

Note 2: One (1) ADS equals eight (8) ordinary shares

Nine Months Ended

September 30,

2008 2007 %

Net revenues:

Laboratory services 130,653 73,539 78%

Manufacturing services 64,715 24,572 163%

Total net revenues 195,368 98,111 99%

Cost of revenues:

Laboratory services (74,652) (36,499)

Manufacturing services (51,549) (14,666)

Total cost of revenues (126,201) (51,165)

Gross Profit 69,167 46,946 47%

Operating expenses:

Selling and marketing expenses (5,427) (1,683) 222%

General and administrative expenses (35,342) (24,415) 45%

Total operating expenses (40,769) (26,098) 56%

Operating income 28,398 20,848 36%

Other income (expenses), net:

Other income (expenses), net (541) 842

Interest income (expenses), net 644 589

Total other income (expenses), net 103 1,431

Income before income taxes 28,501 22,279 28%

Income taxes 1,147 (507)

Net income 29,648 21,772 36%

Amount attributed to:

Deemed dividend on issuance and

repurchase of preference shares -- (7,612)

Amounts allocated to preference

shares for participating rights to

dividends -- (5,729)

Income attributable to holders of ADS

(Note 2):

Basic 29,648 8,431

Diluted 29,648 8,431

Basic earnings per ADS (Note 2) 0.47 0.27

Diluted earnings per ADS (Note 2) 0.41 0.22

Weighted average ADS outstanding -

basic (Note 2) 63,010,497 30,860,969

Weighted average ADS outstanding -

diluted (Note 2) 72,859,672 37,772,585

Note 2: One (1) ADS equals eight (8) ordinary shares

WUXI PHARMATECH (CAYMAN) INC.

RECONCILIATION OF NON-GAAP TO GAAP

(in thousands of U.S. Dollars, except share data and par value data)

Three Months Ended Nine Months Ended

September 30, September 30,

2008 2007 % 2008 2007 %

Non-GAAP

Reconciliation

GAAP gross profit 22,811 16,000 43% 69,167 46,946 47%

GAAP gross margin 34% 47% 35% 48%

Adjustments

Share-based

Compensation 672 310 2,016 1,720

Amortization

of acquired

intangible assets 3,950 -- 10,532 --

Non-GAAP gross

profit 27,433 16,310 68% 81,715 48,666 68%

Non-GAAP gross

margin 41% 48% 42% 50%

GAAP operating

income 9,012 7,500 20% 28,398 20,848 36%

GAAP operating

margin 13% 22% 15% 21%

Adjustments

Share-based

compensation 3,128 1,475 9,526 6,261

Amortization

of acquired

intangible assets 3,950 -- 10,532 --

Non-GAAP

operating income 16,090 8,975 79% 48,456 27,109 79%

Non-GAAP

operating margin 24% 26% 25% 28%

GAAP net income 7,267 8,647 (16%) 29,648 21,772 36%

GAAP net margin 11% 25% 15% 22%

Adjustments

Share-based

compensation 3,128 1,475 9,526 6,261

Amortization

of acquired

intangible assets 3,950 -- 10,532 --

Deferred tax

impact related

to acquired

intangible assets (1,548) -- (4,129) --

Non-GAAP net income 12,797 10,122 26% 45,577 28,033 63%

Non-GAAP net margin 19% 30% 23% 29%

GAAP net income 7,267 8,647 29,648 21,772

Add back:

Depreciation

and amortization 8,797 2,724 23,594 6,223

Interest income

(expenses), net (148) (1,334) (644) (589)

Income taxes 826 178 (1,147) 507

EBITDA 16,742 10,215 64% 51,451 27,913 84%

Adjustments

Share-based

compensation 3,128 1,475 9,526 6,261

Adjusted EBITDA 19,870 11,690 70% 60,977 34,174 78%

Income

attributable

to holders of

ADS (Non- GAAP):

Basic 12,797 8,039 45,577 16,690

Diluted 12,797 8,069 45,577 16,690

Basic earnings

per ADS (Non-GAAP) 0.20 0.18 0.72 0.54

Diluted

earnings per

ADS (Non-GAAP) 0.18 0.15 0.63 0.44

Weighted

average ADS

outstanding -

basic 64,531,068 44,774,893 63,010,497 30,860,969

Weighted

average ADS

outstanding -

diluted 72,931,421 55,496,657 72,859,672 37,772,585

For more information, please contact:

Debra Yu, MD

Vice President Strategy

WuXi PharmaTech (Cayman) Inc.

Tel: +1-215-218-5559

Email: ir@wuxiapptec.com

Dr. Hai Mi

Executive Director of Investor Relations and Business Planning

WuXi PharmaTech (Cayman) Inc.

Tel: +86-21-5046-3726

Email: ir@wuxiapptec.com

Juliane Snowden

Vice President of Investor Relations

Burns McClellan

Tel: +1-212-213-0006

Email: Jsnowden@burnsmc.com


'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2008 PR Newswire.
All rights reserved


Related biology technology :

1. WuXi PharmaTech Signs New Collaboration Agreement With Pfizer
2. WuXi PharmaTech Schedules Third Quarter 2008 Earnings Release on Wednesday, November 12, 2008
3. WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance
4. WuXi PharmaTech Appoints Jeff Leng to Its Board of Directors
5. Matthew B. Wiener, CEO of Pharmatech, Inc., Is Awarded the Cancer Leadership Award From the Colorado Cancer Coalition
6. WuXi PharmaTech (NYSE:WX) Maintains Original Strategy to Provide Toxicology Services in China
7. WuXi PharmaTech Promotes Dr. Rujian Ma to VP of Synthetic Chemistry
8. Warburg Pincus Acquires 5.4% of WuXi PharmaTechs Outstanding Ordinary Shares from United Overseas Bank
9. WuXi PharmaTech (NYSE: WX) Wins the 2008 Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology
10. WuXi PharmaTech (NYSE: WX) Appoints Dr. Debra Yu as VP of Strategy
11. WuXi PharmaTech (NYSE: WX) Named the Most Innovative Company in China and CEO Dr. Li the Most Innovative Leader of Chinese Enterprises
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... Superior Controls, Inc ... today announced the company has successfully completed its 50th consecutive audit. For ... systems integration services to leading companies in life sciences, food and beverage, energy ...
(Date:12/6/2016)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... of its previously-announced cash tender offers (the "Offers") ... accrued and unpaid interest to, but not including, ... expenses related to the Offers) (the "Maximum Tender ... table below (collectively, the "Notes"). The terms and ...
(Date:12/5/2016)... , Dec. 5, 2016 Axovant Sciences ... biopharmaceutical company focused on the treatment of dementia, today ... for the treatment of Alzheimer,s disease will be presented ... Meeting on Friday, December 9, 2016 in ... show results of both simple and complex measures of ...
(Date:12/5/2016)... December 5, 2016 According ... Market, by Products (Consumable, Instruments, Automated Cell Expansion ... and Stem Cell Research, Cancer, and Cell-Based Research), ... Banks) - Global Revenue, Trends, Growth, Share, Size ... Research, the global cell expansion market is expected ...
Breaking Biology Technology:
(Date:11/22/2016)... 22, 2016   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that the ... and Life Sciences Awards as "Most Outstanding in ... unprecedented year of recognition and growth for MedNet, which ... years. iMedNet ™ , MedNet,s ...
(Date:11/17/2016)... OF INDUSTRY, Calif. , Nov. 17, 2016  AIC announces that it has ... using NVMe storage servers in organizations that require high-performance scale-out plus high speed data transfer storage ... ... ... Setting up ...
(Date:11/14/2016)... Technology, Inc. ("xG" or the "Company") (Nasdaq: XGTI, XGTIW), ... in challenging operating environments, announced its results for the ... a conference call to discuss these results on November ... Key Recent Accomplishments ... acquire Vislink Communication Systems. The purchase is expected to ...
Breaking Biology News(10 mins):